期刊
JOURNAL OF CLINICAL ONCOLOGY
卷 28, 期 16, 页码 2768-2776出版社
AMER SOC CLINICAL ONCOLOGY
DOI: 10.1200/JCO.2009.23.8931
关键词
-
类别
资金
- National Cancer Institute [R01 CA133049]
- NATIONAL CANCER INSTITUTE [K05CA124477, R01CA133049, P50CA116201] Funding Source: NIH RePORTER
Evidence has emerged that the clinical benefit of tamoxifen is related to the functional status of the hepatic metabolizing enzyme cytochrome P450 2D6 (CYP2D6). CYP2D6 is the key enzyme responsible for the generation of the potent tamoxifen metabolite, endoxifen. Multiple studies have examined the relationship of CYP2D6 status to breast cancer outcomes in tamoxifen-treated women; the majority of studies demonstrated that women with impaired CYP2D6 metabolism have lower endoxifen concentrations and a greater risk of breast cancer recurrence. As a result, practitioners must be aware that some of the most commonly prescribed medications co-administered with tamoxifen interfere with CYP2D6 function, thereby reducing endoxifen concentrations and potentially increasing the risk of breast cancer recurrence. After reviewing the published data regarding tamoxifen metabolism and the evidence relating CYP2D6 status to breast cancer outcomes in tamoxifen-treated patients, we are providing a guide for the use of medications that inhibit CYP2D6 in patients administered tamoxifen. J Clin Oncol 28:2768-2776. (C) 2010 by American Society of Clinical Oncology
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据